|
Patient's information
|
|
Ageing(≥ 65y)
|
23
|
17
|
0.031
|
|
Male gender
|
23
|
26
|
0.675
|
|
Smoking
|
3
|
6
|
0.506
|
|
BMI (body mass index)
|
25.4 ± 6.0
|
25.1 ± 3.9
|
0.845
|
|
Coronary artery
|
5
|
5
|
0.997
|
|
Diabetes
|
5
|
11
|
0.224
|
|
Hypertension
|
24
|
26
|
0.512
|
|
Prehospital intubation
|
2
|
5
|
0.287
|
|
APACHE II
|
14.3 ± 4.0
|
13.4 ± 3.7
|
0.274
|
|
GCS
|
7.8 ± 2.0
|
7.9 ± 2.4
|
0.864
|
|
Drug use (cumulative use time > = 3d)
|
|
Norepinephrine
|
19
|
20
|
0.527
|
|
Glucocorticoid
|
11
|
13
|
0.918
|
|
Mannitol
|
34
|
43
|
0.705
|
|
Therapeutic hypothermia
|
13
|
8
|
0.074
|
|
Carbapenem antibiotics
|
5
|
7
|
0.806
|
|
Propofol or propofol medium and long chain fat emulsion
|
26
|
36
|
0.387
|
|
Midazolam
|
27
|
36
|
0.641
|
|
Remifentanil or fentanyl
|
36
|
44
|
1.000
|
|
Proton pump inhibitor
|
34
|
46
|
0.289
|
|
H 2 receptor antagonist
|
6
|
3
|
0.291
|
|
Laboratory testing (At the time of intubation)
|
|
ALB (g/l)
|
33.0 ± 6.7
|
32.5 ± 6.7
|
0.752
|
|
CRP (mg/l)
|
61.4 ± 46.7
|
60.6 ± 47.3
|
0.936
|
|
PCT (ng/mL), median (IQR)
|
0.220 (0.10–0.5200)
|
0.120 (0.080–0.500)
|
0.148
|
|
ALT (U/l), median (IQR)
|
29.00 (18.25–33.00)
|
30.00 (19.00–33.5)
|
0.944
|
|
Scr (mmol/l), median (IQR)
|
65.50 (51.25–83.00)
|
58.00 (43.00–81.00)
|
0.180
|
|
White blood cell count (× 109/l)
|
13.4 ± 5.0
|
12.5 ± 3.8
|
0.317
|
|
Neutrophils (× 109/l)
|
11.9 ± 4.7
|
12.6 ± 12.2
|
0.734
|
|
Lymphocyte (× 109/l)
|
0.95 ± 0.46
|
0.87 ± 0.38
|
0.373
|
|
Platelet (× 109/l)
|
180.9 ± 66.5
|
175.3 ± 61.7
|
0.683
|
|
Laboratory testing (on day 7 after intubation)
|
|
ALB (g/l)
|
33.8 ± 5.1
|
32.8 ± 5.1
|
0.367
|
|
ALT (U/l), median (IQR)
|
36.50 (30.00–62.75)
|
46.00 (31.00–60.5)
|
0.468
|
|
Scr (mmol/l), median (IQR)
|
63.5 (45.50–93.00)
|
52.00 (42.00–76.5)
|
0.198
|
|
Laboratory testing (EOVAP group: when pneumonia was diagnosed, non-EOVAP group: on day 7 after intubation)
|
|
CRP (mg/l), median (IQR)
|
76.45 (53.38–111.00)
|
55.00 (30.25–64.75)
|
0.008
|
|
PCT (ng/ml), median (IQR)
|
0.22 (0.13–0.44)
|
0.120 (0.075–0.310)
|
0.047
|
|
White blood cell count (× 109/l)
|
9.4 ± 3.6
|
9.7 ± 3.2
|
0.689
|
|
Neutrophils (× 109/l)
|
7.8 ± 3.4
|
7.9 ± 3.0
|
0.891
|
|
Lymph (× 109/l) median (IQR)
|
0.8(0.58–1.22)
|
0.97 (0.73–1.36)
|
0.108
|
|
Platelet (× 109/l)
|
147.4 ± 63.4
|
177.6 ± 76.2
|
0.044
|
|
MDRB
|
7
|
7
|
0.679
|
|
Outcomes of EOVAP and non-EOVAP groups
|
|
Mechanical ventilation time (h) median (IQR)
|
384(301–493)
|
290(207–432)
|
0.02
|
|
ICU stays (d)
|
19.4 ± 9.6
|
20.3 ± 11.0
|
0.676
|
|
Hospital stays (d)
|
24.8 ± 14.6
|
23.5 ± 11.7
|
0.628
|
|
28-day mortality (d)
|
8
|
7
|
0.474
|